DE69835167D1 - 1,2,4-benzotriazin-oxide enthaltende zubereitungen - Google Patents

1,2,4-benzotriazin-oxide enthaltende zubereitungen

Info

Publication number
DE69835167D1
DE69835167D1 DE69835167T DE69835167T DE69835167D1 DE 69835167 D1 DE69835167 D1 DE 69835167D1 DE 69835167 T DE69835167 T DE 69835167T DE 69835167 T DE69835167 T DE 69835167T DE 69835167 D1 DE69835167 D1 DE 69835167D1
Authority
DE
Germany
Prior art keywords
oxide containing
containing preparations
benzotriazine oxide
benzotriazine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835167T
Other languages
English (en)
Other versions
DE69835167T2 (de
DE69835167T8 (de
Inventor
Stephen Brown
Edward Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Synthelabo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo Inc filed Critical Sanofi Synthelabo Inc
Application granted granted Critical
Publication of DE69835167D1 publication Critical patent/DE69835167D1/de
Publication of DE69835167T2 publication Critical patent/DE69835167T2/de
Publication of DE69835167T8 publication Critical patent/DE69835167T8/de
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE69835167T 1997-04-21 1998-04-14 1,2,4-benzotriazin-oxide enthaltende zubereitungen Expired - Fee Related DE69835167T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/837,637 US5827850A (en) 1995-09-25 1997-04-21 1,2,4-benzotriazine oxides formulations
US837637 1997-04-21
PCT/US1998/007391 WO1998047512A1 (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations

Publications (3)

Publication Number Publication Date
DE69835167D1 true DE69835167D1 (de) 2006-08-17
DE69835167T2 DE69835167T2 (de) 2007-06-06
DE69835167T8 DE69835167T8 (de) 2007-12-06

Family

ID=25275027

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835167T Expired - Fee Related DE69835167T8 (de) 1997-04-21 1998-04-14 1,2,4-benzotriazin-oxide enthaltende zubereitungen

Country Status (13)

Country Link
US (2) US5827850A (de)
EP (1) EP1044005B1 (de)
JP (1) JP2001523248A (de)
AT (1) ATE332139T1 (de)
AU (1) AU6969098A (de)
BR (1) BR9808958A (de)
CA (1) CA2287257C (de)
DE (1) DE69835167T8 (de)
DK (1) DK1044005T3 (de)
ES (1) ES2267183T3 (de)
NO (1) NO325275B1 (de)
PT (1) PT1044005E (de)
WO (1) WO1998047512A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
CA2567574C (en) 2004-04-08 2013-01-08 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ553492A (en) 2004-08-25 2010-11-26 Targegen Inc Triazole derivatives and methods of use
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法
CN101683346B (zh) * 2008-09-24 2015-04-01 杭州民生药业有限公司 一种替拉扎明非肠道含水制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
CN100366253C (zh) * 1995-09-25 2008-02-06 赛诺菲-安万特美国有限责任公司 1,2,4-苯并三嗪氧化物制剂

Also Published As

Publication number Publication date
NO995109D0 (no) 1999-10-20
DE69835167T2 (de) 2007-06-06
NO325275B1 (no) 2008-03-17
DE69835167T8 (de) 2007-12-06
JP2001523248A (ja) 2001-11-20
BR9808958A (pt) 2000-08-01
EP1044005B1 (de) 2006-07-05
CA2287257C (en) 2007-06-12
AU6969098A (en) 1998-11-13
WO1998047512A1 (en) 1998-10-29
EP1044005A4 (de) 2001-08-08
ES2267183T3 (es) 2007-03-01
US5827850A (en) 1998-10-27
ATE332139T1 (de) 2006-07-15
NO995109L (no) 1999-12-21
CA2287257A1 (en) 1998-10-29
DK1044005T3 (da) 2006-09-25
PT1044005E (pt) 2006-10-31
EP1044005A1 (de) 2000-10-18
US6153610A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
EP1423107A4 (de) Fettalkohol-arzneimittel-konjugate
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
NO932954L (no) 2,4-diaminokinazolin-derivater for aa oppnaa oeket antitumoraktivitet
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DE69835167T8 (de) 1,2,4-benzotriazin-oxide enthaltende zubereitungen
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
EP1364657A4 (de) Mittel gegen tumoren in hämatopoetischen organen
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
CA2232989A1 (en) 1,2,4-benzotriazine oxides formulations
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS U.S. LLC, BRIDGEWATER, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee